We’ve rebranded some of our products, learn more ›
CODEX® is now PhenoCycler, Phenoptics™ is now Phenolmager.
Spatial Omics for Targeted Cancer Immunotherapies
Webinar | Tuesday, July 30, 2024
Immune checkpoint inhibitors have emerged as an effective treatment for various cancer types. Anti-PD-1/PD-L1 immune checkpoint inhibitor therapy provides a durable effect when given to patients likely to respond, however, identifying these patients remains a challenge. Therefore, focusing on developing a consistently predictive biomarker to guide patient selection for highly targeted checkpoint inhibitor therapies is key.
In this webinar, Dr. Arutha Kulasinghe, NHMRC Research Fellow and Clinical-oMx Group Leader at the Frazer Institute, University of Queensland, will discuss how single-cell multiomic spatial phenotyping is an invaluable tool to characterize the tumor microenvironment using unbiased whole-slide imaging of metastatic/recurrent HNSCC tumors among patients treated with pembrolizumab/nivolumab. He will also explain how using these techniques, his team were able to identify stromal, immune, and metabolic tissue signatures associated with resistance to immunotherapy and poor overall survival.
Learning Objectives:
- Understand spatial biology approaches
- Learn how to profile deep tumor microenvironments
- Understand how to decode immunotherapy responses
- Discover applications for skin, lung and head, and neck cancer
Video
Speaker
Arutha Kulasinghe, PhD
Scientific Director of the Queensland Spatial Biology Center in Brisbane, Group Leader at The University of Queensland
Biography
Arutha Kulasinghe is a Peter Doherty NHMRC Research Fellow and leads the 'Clinical-oMx Lab' at the University of Queensland. Kulasinghe has pioneered spatial transcriptomics using digital spatial profiling approaches in the Asia-Pacific region, contributing to world-first studies for lung cancer, head and neck cancer, and COVID-19. His research aims to understand the underlying pathobiology by using an integrative multi-omics approach. Kulasinghe has published his research in 60 manuscripts and is supported by the NHMRC, the Australian Academy of Sciences, Cancer Australia, Cure Cancer, MRFF, and numerous philanthropic and hospital foundations.
